Cargando…
Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic
BACKGROUND: Fingolimod (Gilenya®) is approved for relapsing forms of multiple sclerosis in the USA. Owing to transient heart-rate effects when initiating fingolimod, eligible patients undergo precautionary baseline assessment and first-dose observation (FDO) for ≥6 h. Prior to 2014, FDO was undertak...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857316/ https://www.ncbi.nlm.nih.gov/pubmed/31729968 http://dx.doi.org/10.1186/s12883-019-1506-0 |